Severin Investments LLC Buys New Shares in Ascendis Pharma A/S $ASND

Severin Investments LLC bought a new stake in Ascendis Pharma A/S (NASDAQ:ASND) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 2,246 shares of the biotechnology company’s stock, valued at approximately $479,000.

Other institutional investors have also recently added to or reduced their stakes in the company. Advisory Services Network LLC purchased a new stake in Ascendis Pharma A/S during the third quarter valued at about $26,000. Leonteq Securities AG purchased a new stake in Ascendis Pharma A/S during the fourth quarter valued at about $36,000. Jones Financial Companies Lllp grew its position in Ascendis Pharma A/S by 57.2% during the third quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 83 shares during the period. Global Retirement Partners LLC grew its position in Ascendis Pharma A/S by 111.9% during the fourth quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 113 shares during the period. Finally, Quadrant Capital Group LLC purchased a new stake in Ascendis Pharma A/S during the third quarter valued at about $74,000.

Insider Transactions at Ascendis Pharma A/S

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 400 shares of Ascendis Pharma A/S stock in a transaction that occurred on Tuesday, May 26th. The stock was purchased at an average price of $237.80 per share, with a total value of $95,120.00. Following the completion of the acquisition, the director owned 400 shares of the company’s stock, valued at approximately $95,120. This trade represents a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Flemming Steen Jensen sold 19,460 shares of the stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The disclosure for this sale is available in the SEC filing. Corporate insiders own 40.00% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on ASND shares. Wedbush reissued an “outperform” rating and set a $273.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, April 9th. Stifel Nicolaus set a $332.00 price target on Ascendis Pharma A/S in a research report on Wednesday, March 4th. Wall Street Zen raised Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Wolfe Research reissued an “outperform” rating and set a $260.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, March 2nd. Finally, Barclays boosted their price target on Ascendis Pharma A/S from $342.00 to $345.00 and gave the company an “overweight” rating in a research report on Monday, May 11th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $295.39.

Ascendis Pharma A/S Trading Down 1.8%

Shares of ASND opened at $235.26 on Thursday. The company has a market capitalization of $14.68 billion, a P/E ratio of 27.13 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $156.56 and a one year high of $250.74. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.72 and a current ratio of 1.00. The stock has a 50-day moving average price of $233.40 and a 200 day moving average price of $222.79.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.21 by $0.11. The business had revenue of $285.45 million during the quarter, compared to analysts’ expectations of $362.47 million. Sell-side analysts forecast that Ascendis Pharma A/S will post 11.73 EPS for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.